<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561466</url>
  </required_header>
  <id_info>
    <org_study_id>beza16</org_study_id>
    <nct_id>NCT04561466</nct_id>
  </id_info>
  <brief_title>Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy</brief_title>
  <acronym>Béfinohl</acronym>
  <official_title>Study of Efficacy of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Necker-Enfants Malades</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Georges Pompidou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CLAIROP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hôpital Necker-Enfants Malades</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the efficiency of Béfizal® 200 mg in 14 adult patients with a LHON that occurred for&#xD;
      less than 5 years. Patient must have certain specific mutations&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study of the efficiency of Béfizal® 200 mg in 14 adult patients in whom the diagnosis of LHON&#xD;
      obtained on anamnestic, clinical and ancillary testing / laboratory data. LHON should have&#xD;
      occurred for less than 5 years and must be genetically proved with a 3460 or 11778&#xD;
      mitochondrial DNA mutation. Given the mode of transmission, genetic research may have been&#xD;
      carried out in a maternal relative&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">March 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 9, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of best corrected farsight visual acuity (in LogMAR)</measure>
    <time_frame>Month12</time_frame>
    <description>Measurement of the best corrected farsight visual acuity by Early Treatment Diabetic Retinopathy Study type scale (range from -0.3 to 2.6) -0.3 is the best vision and 2.6 the worse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Farsight best corrected visual acuity</measure>
    <time_frame>Month 3</time_frame>
    <description>Measurement of the Farsight best corrected visual acuity in LogMAR by Early Treatment Diabetic Retinopathy Study type scale (range from -0.3 to 2.6) -0.3 is the best vision and 2.6 the worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Farsight best corrected visual acuity</measure>
    <time_frame>Month 6</time_frame>
    <description>Measurement of the Farsight best corrected visual acuity in LogMAR by Early Treatment Diabetic Retinopathy Study type scale (range from -0.3 to 2.6) -0.3 is the best vision and 2.6 the worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Farsight best corrected visual acuity</measure>
    <time_frame>Month 9</time_frame>
    <description>Measurement of the Farsight best corrected visual acuity in LogMAR by Early Treatment Diabetic Retinopathy Study type scale (range from -0.3 to 2.6) -0.3 is the best vision and 2.6 the worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Farsight best corrected visual acuity</measure>
    <time_frame>Month 15</time_frame>
    <description>Measurement of the Farsight best corrected visual acuity in LogMAR by Early Treatment Diabetic Retinopathy Study type scale (range from -0.3 to 2.6) -0.3 is the best vision and 2.6 the worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Farsight best corrected visual acuity</measure>
    <time_frame>Month 3</time_frame>
    <description>Measurement of the Farsight best corrected visual acuity by Early Treatment Diabetic Retinopathy Study type scale (range from -0.3 to 2.6) -0.3 is the best vision and 2.6 the worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Farsight decimal best corrected visual acuity</measure>
    <time_frame>Month 6</time_frame>
    <description>Measurement of the Farsight best corrected visual acuity (in LogMAR) measured with a Monoyer scale (range from 20/20 to light perception). 20/20 is the best vision and light perception the worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Farsight decimal best corrected visual acuity</measure>
    <time_frame>Month 9</time_frame>
    <description>Measurement of the Farsight best corrected visual acuity (in LogMAR) measured with a Monoyer scale (range from 20/20 to light perception). 20/20 is the best vision and light perception the worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Farsight decimal best corrected visual acuity</measure>
    <time_frame>Month 12</time_frame>
    <description>Measurement of the Farsight best corrected visual acuity (in LogMAR) measured with a Monoyer scale (range from 20/20 to light perception). 20/20 is the best vision and light perception the worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Farsight decimal best corrected visual acuity</measure>
    <time_frame>Month 15</time_frame>
    <description>Measurement of the Farsight best corrected visual acuity (in LogMAR) measured with a Monoyer scale (range from 20/20 to light perception). 20/20 is the best vision and light perception the worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Nearsight visual acuity</measure>
    <time_frame>Month 3</time_frame>
    <description>Measurement of the best corrected nearsight visual acuity measured using a Parinaud scale (from P48 to P1&gt;.5) P48 is the worse vision and P1.5 the best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Nearsight visual acuity</measure>
    <time_frame>Month 6</time_frame>
    <description>Measurement of the best corrected nearsight visual acuity measured using a Parinaud scale (from P48 to P1&gt;.5) P48 is the worse vision and P1.5 the best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Nearsight visual acuity</measure>
    <time_frame>Month 9</time_frame>
    <description>Measurement of the best corrected nearsight visual acuity measured using a Parinaud scale (from P48 to P1&gt;.5)P48 is the worse vision and P1.5 the best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Nearsight visual acuity</measure>
    <time_frame>Month 12</time_frame>
    <description>Measurement of the best corrected nearsight visual acuity measured using a Parinaud scale (from P48 to P1&gt;.5) P48 is the worse vision and P1.5 the best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Nearsight visual acuity</measure>
    <time_frame>Month 15</time_frame>
    <description>Measurement of the best corrected nearsight visual acuity measured using a Parinaud scale (from P48 to P1&gt;.5) P48 is the worse vision and P1.5 the best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of retinal nerve fibers layer Optical Coherent Tomography</measure>
    <time_frame>Month 6</time_frame>
    <description>physiological parameter : Optical Coherent Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of retinal nerve fibers layer Optical Coherent Tomography</measure>
    <time_frame>Month 12</time_frame>
    <description>physiological parameter : Optical Coherent Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>automated visual field measurement</measure>
    <time_frame>Month 3</time_frame>
    <description>physiological parameter : automated visual field corrected deviation of a visual field, measured according to a protocol STAT protocol 30 (Champ visuel Métrovision, Perenchies, France)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>automated visual field measurement</measure>
    <time_frame>Month 6</time_frame>
    <description>physiological parameter : automated visual field</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>automated visual field</measure>
    <time_frame>Month 9 of a treatment with BEFIZAL® 200mg (ARROW GENERIQUES) compare to Month 0</time_frame>
    <description>physiological parameter : automated visual field corrected deviation of a visual field, measured according to a protocol STAT protocol 30 (Champ visuel Métrovision, Perenchies, France)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>automated visual field measurement</measure>
    <time_frame>Month 12</time_frame>
    <description>physiological parameter : automated visual field corrected deviation of a visual field, measured according to a protocol STAT protocol 30 (Champ visuel Métrovision, Perenchies, France)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>automated visual field measurement</measure>
    <time_frame>Month 15</time_frame>
    <description>physiological parameter : automated visual field corrected deviation of a visual field, measured according to a protocol STAT protocol 30 (Champ visuel Métrovision, Perenchies, France)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manual visual field measurement</measure>
    <time_frame>Month 3</time_frame>
    <description>physiological parameter : manual visual field measured with isopters V / 4, III / 1 and II / 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manual visual field measurement</measure>
    <time_frame>Month 6</time_frame>
    <description>physiological parameter : manual visual field measured with isopters V / 4, III / 1 and II / 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manual visual field measurement</measure>
    <time_frame>Month 9</time_frame>
    <description>physiological parameter : manual visual field measured with isopters V / 4, III / 1 and II / 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manual visual field measurement</measure>
    <time_frame>Month 12</time_frame>
    <description>physiological parameter : manual visual field measured with isopters V / 4, III / 1 and II / 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manual visual field measurement</measure>
    <time_frame>Month 15</time_frame>
    <description>physiological parameter : manual visual field measured with isopters V / 4, III / 1 and II / 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Eye Institute Visual Function Questionnaire 25</measure>
    <time_frame>Month 12</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of serum creatinine</measure>
    <time_frame>Every three months until Month 15</time_frame>
    <description>Concentration of serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of high-density lipoprotein cholesterol</measure>
    <time_frame>Every three months until Month 15</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of very low-density lipoprotein cholesterol</measure>
    <time_frame>Every three months until Month 15</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of triglycerides</measure>
    <time_frame>Every three months until Month 15</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Partial thromboplastin time</measure>
    <time_frame>Every three months until Month 15</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Aspartate aminotransférase</measure>
    <time_frame>Every three months until Month 15</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Alanine aminotransférase</measure>
    <time_frame>Every three months until Month 15</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of lactate deshydrogenase</measure>
    <time_frame>Every three months until Month 15</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of creatine kinase</measure>
    <time_frame>Every three months until Month 15</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Safety Issues</condition>
  <condition>Efficacy, Self</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 adult patients in whom the diagnosis of LHON obtained on anamnestic, clinical and ancillary testing / laboratory data. LHON should have occurred for less than 5 years and must be genetically proved with a 3460 or 11778 mitochondrial DNA mutation. Given the mode of transmission, genetic research may have been carried out in a maternal relative.&#xD;
Befizal® 200 mg will be tested for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Béfizal</intervention_name>
    <description>600 mf befizal a day for one year</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients in whom the diagnosis of LHON obtained on anamnestic, clinical and&#xD;
             ancillary testing / laboratory data. LHON should have occurred for less than 5 years&#xD;
             and must be genetically proved with a 3460 or 11778 mitochondrial DNA mutation. Given&#xD;
             the mode of transmission, genetic research may have been carried out in a maternal&#xD;
             relative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  * Any optic neuropathy for which the diagnosis of LHON is not formally confirmed or&#xD;
             genetically proven;&#xD;
&#xD;
               -  LHON that started for more than 5 years;&#xD;
&#xD;
               -  LHON associated with another primary mutation than 3460 or 11778&#xD;
&#xD;
               -  Children or adult patients under guardianship or deprived of liberty by&#xD;
                  administrative or judicial decision;&#xD;
&#xD;
               -  Women of childbearing age ; pregnant or lactating women;&#xD;
&#xD;
               -  Patients who do not have affiliation to a social protection scheme (national or&#xD;
                  private insurance / beneficiary or assignee);&#xD;
&#xD;
               -  Patient who did not give its written, informed and signed consent;&#xD;
&#xD;
               -  Allergy to fibrate, bezafibrate and / or BEFIZAL® 200mg (Arrow Generiques) or one&#xD;
                  of these constituents;&#xD;
&#xD;
               -  Photosensitivity reactions related to fibrates;&#xD;
&#xD;
               -  Patient already receiving treatment with fibrates or HMG Co-A reductase&#xD;
                  inhibitors or anticoagulants;&#xD;
&#xD;
               -  Hepatic insuffisiency or dysfunction with increased of transaminases (AST and&#xD;
                  ALT) over 3 times of the normal;&#xD;
&#xD;
               -  Renal insufficiency with serum creatinine&gt; 15 mg / L (&gt; 135 mg / dL) Biliary&#xD;
                  pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Bremond Gignac, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Necker Hopsital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>christophe Orssaud, MD</last_name>
    <phone>33 1 56 09 34 66</phone>
    <email>christophe.orssaud@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>HEGP Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe ORSSAUD, MD</last_name>
      <phone>33 1 56 09 34 98</phone>
      <email>christophe.orssaud@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Dominique Bremond Gignac, MD PhD</last_name>
      <phone>33 1 44 49 45 02</phone>
      <email>dominique.bremond@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Necker-Enfants Malades</investigator_affiliation>
    <investigator_full_name>Christophe Orssaud</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>leber herediatry optic neuropathy</keyword>
  <keyword>befizal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Atrophy, Hereditary, Leber</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bezafibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

